Table 4 Surgical and postoperative information, efficacy and safety in each subgroup of patients receiving preoperative initiation anticoagulation group
Characteristics | Group A | Group B | Group C | Group D | Total | P value |
|---|---|---|---|---|---|---|
(n=54) | (n=57) | (n=15) | (n=7) | (n=133) | ||
Surgical information | ||||||
General anaesthesia, n (%) | 14 (25.93) | 16 (28.07) | 5 (33.33) | 2 (28.57) | 37 (27.82) | |
Surgery time (min),mean ± SD | 171±51 | 175±38 | 168±37 | 187±21 | 173±43 | 0.408 |
Intraoperative bleeding (mL),mean ± SD | 210±89 | 211±171 | 227±234 | 192±142 | 208±183 | 0.805 |
Intraoperative blood transfusion, n (%) | 4 (7.41) | 2 (3.51) | 2 (13.33) | 1 (14.29) | 9 (6.77) | |
Postoperative information | ||||||
Postoperative blood transfusion, n (%) | 6 (11.11) | 9 (15.79) | 4 (26.67) | 3 (42.86) | 22 (16.54) | |
Postoperative drainage (mL),mean ± SD | 201±157 | 203±149 | 259±188 | 260±81 | 212±154 | 0.277 |
Reduction in hemoglobin concentrations (g/L) | 24±11 | 24±10 | 18.±14 | 15±10 | 23±11 | 0.375 |
Hospital stays(days),mean ± SD | 18±4 | 21±4 | 24±7 | 23±7 | 20±5 | 0.00 |
Efficacy assessment, n (%) | ||||||
Symptomatic DVT | 0 (0) | 1 (1.75) | 0 (0) | 0 (0) | 1 (0.75) | |
Symptomatic PE | 1 (1.85) | 0 (0) | 1 (6.67) | 0 (0) | 2 (1.50) | |
Safety assessment, n (%) | ||||||
Major bleeding | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Minor bleeding | 1 (1.85) | 0 (0) | 2 (13.3) | 2 (28.6) | 5 (3.76) | |
Thrombocytopenia | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Elevated aminotransferase | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Suspicious allergic reaction | 0 (0) | 1 (1.75) | 0 (0) | 0 (0) | 1 (0.76) |